Skip to content
Sign in
Public funderBacked 1 network startup

Korea Drug Development Fund (KDDF)

Korean government drug-development fund supporting Korean biotech pipelines, including a 2026 grant to BILIX.

Seoul, South Korea
Ticket
—Not published
Assets under management
—
Founded
—
Stages
—
Network startups backed
1
Co-investors
0

How they invest

Biotech and life sciences in South Korea; grants to drug candidates.

Stage and ticket

Grants.

Geography

South Korea.

What makes them say yes

  • Korean drug-development programme
  • Clinical-stage milestones
  • Korean entity

Red flags

  • No Korean entity

Sectors

  • Biotech & life sciences

Stages

Not published

Geographies

  • South Korea

How to approach

Only for Korean drug developers.

Portfolio

1 network startup · no other company

Grant to BILIX (acute kidney injury).

Gaps in the portfolio

  • Other Korean biotech

Network startups

  • BILIXSWC 2026 Finalist

    KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.

    South Korea · Biotech & life sciences

Network startups that fit

3 analysed

Tampere spin-off building scalable iPSC-derived corneal cell therapy for limbal stem cell deficiency, targeting first clinical trials around 2027.

Finnish cell therapy — no Korean entity.

10%confidence

Evidence from the records

  • “"South Korea"”
  • “Ophthalmic cell therapy (cornea)”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
Intro path
Founder-to-founder intro via BILIX (network portfolio company of Korea Drug Development Fund (KDDF)).
First step
Only with a Korean partner.

Preclinical biotech licensing University of Miami RNA aptamers to regenerate beta cells in type 1 diabetes and target solid tumours.

US aptamers — no Korean entity.

10%confidence

Evidence from the records

  • “South Korea”
  • “RNA aptamers – type 1 diabetes and solid tumors”
  • “No public evidence of traction found: preclinical RNA aptamer pipeline.”
Intro path
Founder-to-founder intro via BILIX (network portfolio company of Korea Drug Development Fund (KDDF)).
First step
Low priority.

HKUST polymer-therapeutics platform entering the clinic in dry eye, with osteoarthritis and aesthetics as follow-on indications.

Chinese polymer therapeutics — no Korean entity.

10%confidence

Evidence from the records

  • “South Korea”
  • “Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerative aesthetics)”
  • “First-in-human trial of candidate P002 (dry eye) authorized by Health Canada (ITA)”
Intro path
Founder-to-founder intro via BILIX (network portfolio company of Korea Drug Development Fund (KDDF)).
First step
Low priority.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

No co-investment documented yet.

Sources

  1. 1thevc.kr/bilix/fundings
  2. 2venturesquare.net/en/1096875/
  3. 3venturesquare.net/1096872/

Profile compiled from public sources. Unknown fields are left empty rather than estimated.